The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million that Nestle had already invested in Aimmune, Nestle said in a statement.from Moneycontrol Business News https://ift.tt/2QEFiGF
Monday, August 31, 2020
Nestle to buy Aimmune Therapeutics, valuing allergy treatment maker at $2.6 billion
The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million that Nestle had already invested in Aimmune, Nestle said in a statement.from Moneycontrol Business News https://ift.tt/2QEFiGF
No comments:
Post a Comment